Clinical Activity and Immune Modulation in Cancer Patients Treated With CP-870,893, a Novel CD40 Agonist Monoclonal Antibody

Vonderheide et al. (Tue,) studied this question.

www.synapsesocial.com/papers/69d9260d8988aeabbe68453c — DOI: https://doi.org/10.1200/jco.2006.08.3311

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Phase I Study of Recombinant Human CD40 Ligand in Cancer Patients· 2001 · 225 citations
2. Molecular and biological characterization of a murine ligand for CD40· 1992 · 1,024 citations
3. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell· 1998 · 2,338 citations
4. The role of the CD40 pathway in the pathogenesis and treatment of cancer· 2004 · 99 citations
5. CD40-CD40 ligand· 2000 · 1,399 citations